Article

Safety, Pharmacokinetics, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptors 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase 1/2 Study in Systemic Lupus Erythematosus

2024-04-27

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Objectives</h4> To evaluate the safety, tolerability, pharmacokinetics (PK), biomarker response, and efficacy of E6742 in a phase 1/2 study in patients with systemic lupus erythematosus (SLE). <h4>Methods</h4> Two sequential cohorts of SLE patients were enrolled and randomized to 12 weeks of twice-daily treatment with E6742 (100 or 200 mg; n = 8 or 9) or placebo (n = 9). <h4>Results</h4> The...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 64259cd0-fc8b-5d4a-ab1f-48ddccd0d16e
DOI: 10.1101/2024.04.26.24306410

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety, Pharmacokinetics, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptors 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase 1/2 Study in Systemic Lupus ErythematosusDOI 10.1101/2024.04.26.24306410Read

Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosusSemantic proximity Read

Update οn the diagnosis and management of systemic lupus erythematosus.Semantic proximity Read

Efficacy and safety of belimumab in immune thrombocytopenia secondary to systemic lupus erythematosusSemantic proximity Read

Identification and immunoassay of biomarkers associated with T cell exhaustion in systemic lupus erythematosusSemantic proximity Read

Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.Semantic proximity Read

Novel biological therapeutic approaches to cutaneous lupus erythematosus.Semantic proximity Read

Mechanistic pharmacokinetic/pharmacodynamic modelling of acute inflammatory challenge modelsSemantic proximity Read

Differential Expression of Toll-Like Receptors 1 and 3 in Patients With Systemic Lupus Erythematosus and Systemic SclerosisSemantic proximity Read

Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infectionSemantic proximity Read

A systematic review of low-dose interleukin-2 for the treatment of systemic lupus erythematosusSemantic proximity Read

Systemic Treatment Strategies for Patients with Psoriasis and Psoriatic Arthritis in the Setting of ANA Positivity or Lupus Spectrum Disease: A Comprehensive Systematic ReviewSemantic proximity Read

Anakinra in the Management of Adult-Onset Still’s Disease: A Single-Center ExperienceSemantic proximity Read